Christie Schumacher

Christie Schumacher

Auto-generated profile, based on publicly available information

Christie Schumacher

Midwestern University College of Pharmacy, Downers Grove Campus Downers Grove Illinois USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2017 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
KBKelly R. Burke
Kelly R. Burke
CSChristine A. Schumacher
Christine A. Schumacher
SHSpencer E. Harpe
Spencer E. Harpe

1 August 2016 in American Journal of Pharmaceutical Education
Verified
Journal Article
Open access
PDF file
JPJennifer A. Phillips
Jennifer A. Phillips
CSChristie Schumacher
Christie Schumacher
SASally Arif
Sally Arif
Objective. To evaluate student perception and time spent on asynchronous online lectures in a blended learning environment (BLE) and to assess faculty workload and perception. Methods. Students (n=427) time spent viewing online lectures was measured in three courses. Students and faculty members completed a survey to assess perceptions of a BLE. Faculty members recorded time spent creating BLEs. Results. Total time spent in the BLE was less than the allocated time for two of the three courses by 3-15%. Students preferred online lectures for their flexibility, students’ ability to apply information learned, and congruence with their learning styles. Faculty members reported the BLE facilitated higher levels of learning during class sessions but noted an increase in workload. Conclusion. A BLE increased faculty workload but was well received by students. Time spent viewing online lectures was less than what was allocated in two of the three courses.

10 February 2020 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
PSPaul M. Stranges
Paul M. Stranges
CJCynthia A. Jackevicius
Cynthia A. Jackevicius
SASarah L. Anderson
Sarah L. Anderson
DBDeborah S. Bondi
Deborah S. Bondi
IDIlya Danelich
Ilya Danelich
SSSean Smithgall
Sean Smithgall

22 February 2019 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
EDElizabeth Van Dril
Elizabeth Van Dril
CSChristie Schumacher
Christie Schumacher
Introduction: Use of continuous glucose monitoring (CGM) in the management of diabetes continues to grow. Despite professional‐use CGM serving as an opportunity for clinical pharmacists to improve care and generate revenue for managing patients with diabetes, there is limited literature describing their involvement with this technology.Objectives: The primary objective was to determine if professional CGM improves measures of glycemic control including percentage of time in target glycemic range, change in estimated average interstitial glucose, and change in hemoglobin A1c (HbA1c) from baseline to postintervention. Secondary objectives were to evaluate revenue generation measured by reimbursement rates for Current Procedural Terminology (CPT) codes 95250 and 95251 and utilization of clinical pharmacist services related to professional CGM.Methods: This was a quasi‐experimental, retrospective, pre‐post intervention analysis. Patients that had a professional CGM placed and more than 24 hours of data interpreted by a clinical pharmacist were included for analysis. All clinical data were extracted from patients' electronic medical records, while reimbursement data were provided by the organization's billing department.Results: Twenty‐nine patients that received professional CGM were included for analysis. Patients' mean baseline and post‐intervention HbA1c were 9.0% and 8.3%, respectively (P = 0.156). There was no difference in the mean percentage of time in target glycemic range (P = 0.966) or mean estimated average interstitial glucose (P = 0.779) from baseline to post‐intervention. Patients met with clinical pharmacists for a total of 68 follow‐up visits during their individual 14‐day wear periods, 14 of which were unanticipated visits. The mean payment amount for CPT code 95250 was $126.87, while $39.17 was received for 95251.Conclusions: Clinical pharmacist‐led professional CGM did not demonstrate a statistically significant difference in measures of glycemic control; however, the 14‐day device wear period provided opportunities for optimization of antihyperglycemic therapy that resulted in a clinically significant reduction in HbA1c and reimbursement for clinical pharmacy services.

1 August 2018 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
CSChristie Schumacher
Christie Schumacher
GMGolbarg Moaddab
Golbarg Moaddab
MCMonique Colbert
Monique Colbert
MKMary Ann Kliethermes
Mary Ann Kliethermes
BACKGROUND: Recent changes in the health care delivery landscape have expanded opportunities for clinical pharmacists in the ambulatory care setting. This article describes the successful integration of a clinical pharmacist-led chronic disease management service in a patient-centered medical home (PCMH) and accountable care organization (ACO) environment. PROGRAM DESCRIPTION: In 2008, the year before PCMH implementation, 36% of patients who were hospitalized at Advocate Trinity Hospital for a heart failure exacerbation were readmitted within 30 days of their hospital stay for heart failure exacerbation. This high rate of heart failure hospital readmissions, compared with national standards, drove the implementation of the PCMH at Advocate Medical Group – Southeast Center (AMG-SE), the adjoining outpatient medical clinic. A clinical pharmacist was added to the health care team to help achieve the collective goal of improving patient outcomes and decreasing hospitalizations. OBSERVATIONS: From November 1, ...

1 January 2014 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
PDF file
CSChristie Schumacher
Christie Schumacher
SGScott E. Glosner
Scott E. Glosner